



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/992,708	11/19/2001	Glen D. Caby	1023-011US01	7472

28863 7590 01/13/2005
SHUMAKER & SIEFFERT, P. A.
8425 SEASONS PARKWAY
SUITE 105
ST. PAUL, MN 55125

EXAMINER

MULLEN, KRISTEN DROESCH

ART UNIT PAPER NUMBER

3762

DATE MAILED: 01/13/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/992,708	Applicant(s) CABY ET AL. C	
	Examiner Kristen Mullen	Art Unit 3762	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 11/2/04 (response).
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-42 is/are pending in the application.
- 4a) Of the above claim(s) 9-14 and 23-28 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-8, 15-22 and 29-42 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 19 November 2001 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

2. Claims 1-7, 15-21, 29-30, 32, and 34-41 are rejected under 35 U.S.C. 102(e) as being anticipated by Greeven et al. (6,832,200).

Regarding claims 1, 15, Greeven et al. shows a method and processor readable medium containing instructions comprising: transmitting a USB token packet to a first module of a medical device when the first module has a data packet to transfer, receiving the data packet from the first module; and transferring the data packet to a second module of the medical device using a USB protocol (Col. 5, lines 15-29; Fig. 2). Rosenberg (5,734,373) shows that USB protocol includes a token packet followed by a data packet, which is followed by a handshake packet (Col. 45, lines 5-11).

With respect to claim 29, Greeven et al. shows a device comprising: a system control module (100), a plurality of functional modules (202); and a system bus coupled to the system control module and to the plurality of functional modules, the system bus arranged to transfer data packets between the functional modules and the system control module according to a USB protocol (Col. 5, lines 15-29; Fig. 2).

Regarding claims 2, 16, and 38, Takinosawa (2003/ 0035473) shows that encoding data packets utilizing a NRZI encoding scheme is a component of USB protocol (Para. 0025).

With respect to claims 3, 17, and 39, Pasumansky (6,826,639) shows USB protocol includes control, isochronous, interrupt, and bulk transfer modes (Col. 1, line 62-Col. 2, line 34).

Regarding claim 4, and 18, Pasumansky (6,826,639) shows USB protocol dictates that when one module does not have a data packet to transfer, it sends a indication to the second module which is received by the second module (Col. 1, line 62-Col. 2, line 34).

With respect to claims 5, 19, and 40, Fensore (6,415,343) shows USB protocol includes assigning addresses to each module (Col. 1, lines 57-60)

Regarding claims 6, 20, and 41, Greeven et al. shows associating at least one pipe (204) with each of the first and second modules (Fig. 2).

With respect to claims 7, 21, 30, 32, and 34, Greeven et al. shows the medical device comprises at least one of a therapy control module (100), a user interface module (202-5) and a patient parameters module (202-1 through 202-4).

Regarding claim 35, Greeven et al. shows the patient parameters module (202-1) is configured to obtain at least one of multi-lead ECG measurements, EEG measurements (Col. 5, lines 29-50).

With respect to claims 36-37, Greeven et al. shows the plurality of functional modules comprises an expansion module (202-5) comprising a simple device to communicate data with at least one device external to the medical device system (Col. 8, lines 28-39).

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. Claims 8, 22, 31, and 42 are rejected under 35 U.S.C. 103(a) as being unpatentable over Greeven et al. (6,832,200) in view of Owen et al. (6,148,233). Greeven et al. is as explained before. Although Greeven et al. fails to show the medical device is a defibrillator or the therapy control module comprises a defibrillator electrode, attention is directed to Owen et al. which shows a defibrillator with multiple modules that communicate with one another including a therapy control module including a defibrillation electrode (Fig. 8). It would have been obvious to one with ordinary skill in the art at the time the invention was made to employ the USB data transfer protocol of Greeven et al. for the communication between modules of Owen et al., wherein so doing would amount to mere substitution of one functional equivalent for another that would work equally well on the Owen et al. device.

5. Claim 33 is rejected under 35 U.S.C. 103(a) as being unpatentable over Greeven et al. (6,832,200). Greeven et al. discloses the claimed invention except for the user interface module is communicatively coupled to at least one of a keyboard, a display screen, a strip chart recorder, an LED arrangement, a rotary encoder device, and a touch screen. It would have been an obvious design choice to one with ordinary skill in the art at the time of the invention to communicatively couple the user interface module to at least one of a keyboard, a display screen, a strip chart recorder, an LED arrangement, a rotary encoder device, and a touch screen, since

Art Unit: 3762

applicant has not disclosed that these devices provides any criticality and /or unexpected results and it appears that the invention would perform equally well with any device such as the one way or two way pager, cellular telephone, IR transceiver or wireless device taught by Greeven et al. for communicating with the user input module.

Conclusion


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kristen Mullen whose telephone number is (571) 272-4944. The examiner can normally be reached on M-F, 10:30 am-6:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Angela Sykes can be reached on (571) 272-4955. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



kdm



ANGELA D. SYKES
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 3700